XENE
Xenon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$39.19
+2.51%Nov 2, 2026, 21:01 UTC
Xenon Pharmaceuticals Inc. announced that it will report its third-quarter 2026 financial results and provide a business update after U.S. markets close on November 9, 2026.
Source:Oct 29, 2026, 12:30 UTC
Xenon Pharmaceuticals announced that Phase 2 proof-of-concept studies of XEN1701 and XEN1120 in acute pain are expected to begin in the first half of 2027.
Source:Oct 29, 2026, 12:30 UTC
Xenon Pharmaceuticals announced preclinical data in cynomolgus monkeys showing significant reductions in capsaicin-evoked heat pain for NaV1.7 and KV7 compounds.
Source:Oct 29, 2026, 12:30 UTC
Xenon Pharmaceuticals announced positive Phase 1 results for XEN1701 and XEN1120, reporting that XEN1701 achieved the desired NaV1.7 receptor occupancy and was generally well tolerated, while XEN1120 reached plasma levels predictive of analgesic effects and was generally well tolerated.
Source:Oct 1, 2026, 13:23 UTC
Xenon Pharmaceuticals director, president and CEO Ian Mortimer bought 30,000 company shares for $1,121,400 on September 30, 2026, per a Form 4 filed with the SEC.
Source:Sep 22, 2026, 22:18 UTC
SueWallSt notified investors of a pending investigation into Xenon Pharmaceuticals following the company's disclosure of an enrollment pause in its Phase 3 depression trials for azetukalner, which sent XENE shares down as much as 27.6%.
Source:Sep 22, 2026, 11:47 UTC
Wolf Popper LLP announced an investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. common stock.
Source:Sep 17, 2026, 20:38 UTC
Xenon Pharmaceuticals temporarily paused enrollment of new patients in its clinical studies of an experimental drug for major depression and bipolar disorder following reports of mental and nervous system-related side effects.
Sep 17, 2026, 20:01 UTC
Xenon Pharmaceuticals submitted a New Drug Application to the U.S. Food and Drug Administration for azetukalner for the treatment of focal seizures.
Aug 25, 2026, 07:55 UTC
BlackRock Inc. acquired a new minority stake in Xenon Pharmaceuticals Inc., buying 7,522,482 shares valued at approximately $454.06 million, representing about 7.78% ownership, as disclosed in a 13F filing.
Source:Aug 7, 2026, 05:24 UTC
Xenon Pharmaceuticals Inc. held its Q2 2026 earnings call on August 6, 2026.
Source: